Eribulin effective for earlier treatment of metastatic breast cancer

the ONA take:

According to a new study published in the Journal of Clinical Oncology, researchers have found eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.

For the study, researchers sought to determine the activity of eribulin as an early treatment for metastatic breast cancer.

For the phase 3 study, researchers randomly assigned 1,099 women with metastatic breast cancer who had previously been treated with an anthracycline or a taxane to receive either capecitabine or eribulin as first-, second-, or third-line therapy for metastatic breast cancer.

Results showed that there was no statistical difference in overall survival between capecitabine and eribulin. In addition, a subset analysis found that eribulin may be especially active in those with triple negative metastatic breast cancer, a type of breast cancer that is particularly difficult to treat because it does not respond to hormonal therapy or HER2-targeted therapies.

The findings suggest that eribulin may have a role earlier in the course of the treatment of metastatic breast cancer.

Eribulin effective for earlier treatment of metastatic breast cancer
Eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
An international research team, led by Dartmouth's Peter A. Kaufman, MD, published findings today in the Journal of Clinical Oncology demonstrating that, while not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen.
READ FULL ARTICLE From News Medical
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs